ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TARA Protara Therapeutics Inc

1.69
0.00 (0.00%)
Pre Market
Last Updated: 09:16:39
Delayed by 15 minutes
Share Name Share Symbol Market Type
Protara Therapeutics Inc NASDAQ:TARA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.69 1.50 2.04 0 09:16:39

Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

11/11/2020 12:00pm

GlobeNewswire Inc.


Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more Protara Therapeutics Charts.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that its Chief Executive Officer, Jesse Shefferman, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 1:45pm ET.

A webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived on the Company’s website for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Blaine DavisProtara TherapeuticsBlaine.Davis@protaratx.com646-844-0337

1 Year Protara Therapeutics Chart

1 Year Protara Therapeutics Chart

1 Month Protara Therapeutics Chart

1 Month Protara Therapeutics Chart

Your Recent History

Delayed Upgrade Clock